160 related articles for article (PubMed ID: 26687097)
1. A Japanese, Multicenter, Open-label, Phase 3 Study to Investigate the Safety and Efficacy of Gadobutrol for Contrast-enhanced MR Imaging of the Central Nervous System.
Tanaka A; Masumoto T; Yamada H; Kurauchi M; Breuer J
Magn Reson Med Sci; 2016; 15(2):227-36. PubMed ID: 26687097
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.
Kuwatsuru R; Takahashi S; Umeoka S; Sugihara R; Zeng M; Huan Y; Peng W; Ma L; Guo L; Teng G; Yao W; Tozaki M; Endo M; Kaji S; Ro T; Tae Hahn S; Chul Kang B; Nishimura H; Sugawara Y; Katakami N; Breuer J; Aitoku Y
J Magn Reson Imaging; 2015 Feb; 41(2):404-13. PubMed ID: 24692302
[TBL] [Abstract][Full Text] [Related]
4. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
Liu BP; Rosenberg M; Saverio P; Weon YC; Peters S; Ardellier FD; Boeckenhoff A; Endrikat J
AJR Am J Roentgenol; 2021 Nov; 217(5):1195-1205. PubMed ID: 34133205
[No Abstract] [Full Text] [Related]
6. Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study.
Gutierrez JE; Rosenberg M; Seemann J; Breuer J; Haverstock D; Agris J; Balzer T; Anzalone N
Magn Reson Insights; 2015; 8():1-10. PubMed ID: 25922578
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.
Loevner LA; Kolumban B; Hutóczki G; Dziadziuszko K; Bereczki D; Bago A; Pichiecchio A
Invest Radiol; 2023 May; 58(5):307-313. PubMed ID: 36729404
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Kuhl C; Csőszi T; Piskorski W; Miszalski T; Lee JM; Otto PM
Radiology; 2023 Jul; 308(1):e222612. PubMed ID: 37462494
[TBL] [Abstract][Full Text] [Related]
11. Gadobutrol-Enhanced Magnetic Resonance Imaging of the Breast in the Preoperative Setting: Results of 2 Prospective International Multicenter Phase III Studies.
Sardanelli F; Newstead GM; Putz B; Jirakova Trnkova Z; Trimboli RM; Abe H; Haverstock D; Rosenberg M
Invest Radiol; 2016 Jul; 51(7):454-61. PubMed ID: 26840494
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine.
Chang JM; Moon WK; Cha JH; Jung EJ; Cho N; Kim SJ
Invest Radiol; 2010 Oct; 45(10):655-61. PubMed ID: 20808238
[TBL] [Abstract][Full Text] [Related]
13. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study).
Maravilla KR; San-Juan D; Kim SJ; Elizondo-Riojas G; Fink JR; Escobar W; Bag A; Roberts DR; Hao J; Pitrou C; Tsiouris AJ; Herskovits E; Fiebach JB
AJNR Am J Neuroradiol; 2017 Sep; 38(9):1681-1688. PubMed ID: 28663267
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
[TBL] [Abstract][Full Text] [Related]
16. Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast-enhanced magnetic resonance imaging.
Renz DM; Durmus T; Böttcher J; Taupitz M; Diekmann F; Huppertz A; Pfeil A; Maurer MH; Streitparth F; Bick U; Hamm B; Fallenberg EM
Invest Radiol; 2014 Jul; 49(7):474-84. PubMed ID: 24637587
[TBL] [Abstract][Full Text] [Related]
17. Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study.
Glutig K; Bhargava R; Hahn G; Hirsch W; Kunze C; Mentzel HJ; Schaefer JF; Willinek W; Palkowitsch P;
Pediatr Radiol; 2016 Aug; 46(9):1317-23. PubMed ID: 27041276
[TBL] [Abstract][Full Text] [Related]
18. Focal liver lesions: detection and characterization at double-contrast liver MR Imaging with ferucarbotran and gadobutrol versus single-contrast liver MR imaging.
Heilmaier C; Lutz AM; Bolog N; Weishaupt D; Seifert B; Willmann JK
Radiology; 2009 Dec; 253(3):724-33. PubMed ID: 19789232
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
[TBL] [Abstract][Full Text] [Related]
20. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.
Anzalone N; Scarabino T; Venturi C; Cristaudo C; Tartaro A; Scotti G; Zimatore D; Floris R; Carriero A; Longo M; Cirillo M; Cova MA; Gatti S; Voth M; Colosimo C
Eur J Radiol; 2013 Jan; 82(1):139-45. PubMed ID: 21890295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
